Eyecelerator
Conference Video Presentations
Presented at American Society of Cataract and Refractive Surgery 2022
Filter by:
Favorable Safety and Tolerability Profile of Oral APX3330 Drives Dosing Strategy for Ongoing Phase 2 Trial for DR/DME
APX3330
Presented at American Academy of Ophthalmology 2021
VEGA-1 Phase 2 Clinical Trial To Evaluate The Efficacy Of Phentolamine Ophthalmic Solution And Low-Dose Pilocarpine For The Treatment Of Presbyopia
NYXOL
Presented at American Academy of Ophthalmology 2021
VEGA-1 Phase 2 Clinical Trial To Evaluate The Efficacy Of Phentolamine Ophthalmic Solution And Low-Dose Pilocarpine For The Treatment Of Presbyopia
NYXOL
Presented at American Society of Cataract and Refractive Surgery 2021
MIRA-2 Phase 3 Clinical Trial to Evaluate the Efficacy of Phentolamine Ophthalmic Solution on the Reversal of Pharmacologically Induced Mydriasis
NYXOL
Presented at American Society of Cataract and Refractive Surgery 2021
Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modeling
APX3330
Indiana University School of Medicine
Bridging population pharmacokinetic and physiologically based pharmacokinetic approaches to evaluate APX3330 disposition
APX3330
Indiana University School of Medicine
Phentolamine Eye Drops Reverse Pharmacologically Induced Mydriasis in a Randomized Phase 2b Trial
NYXOL
Optometry and Vision Science
